PL2131847T3 - Lek zawierający przynajmniej jeden gestagen - Google Patents

Lek zawierający przynajmniej jeden gestagen

Info

Publication number
PL2131847T3
PL2131847T3 PL08716068T PL08716068T PL2131847T3 PL 2131847 T3 PL2131847 T3 PL 2131847T3 PL 08716068 T PL08716068 T PL 08716068T PL 08716068 T PL08716068 T PL 08716068T PL 2131847 T3 PL2131847 T3 PL 2131847T3
Authority
PL
Poland
Prior art keywords
hydroxy
gestagen
optionally
chlormadinone acetate
pregnadien
Prior art date
Application number
PL08716068T
Other languages
English (en)
Inventor
Georg Schramm
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of PL2131847T3 publication Critical patent/PL2131847T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL08716068T 2007-03-07 2008-02-27 Lek zawierający przynajmniej jeden gestagen PL2131847T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102007011486A DE102007011486A1 (de) 2007-03-07 2007-03-07 Arzneimittel umfassend wenigstens ein Gestagen
EP08716068A EP2131847B1 (de) 2007-03-07 2008-02-27 Arzneimittel umfassend wenigstens ein gestagen
PCT/EP2008/001532 WO2008107099A1 (de) 2007-03-07 2008-02-27 Arzneimittel umfassend wenigstens ein gestagen

Publications (1)

Publication Number Publication Date
PL2131847T3 true PL2131847T3 (pl) 2011-05-31

Family

ID=39322828

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08716068T PL2131847T3 (pl) 2007-03-07 2008-02-27 Lek zawierający przynajmniej jeden gestagen

Country Status (7)

Country Link
US (1) US8361995B2 (pl)
EP (1) EP2131847B1 (pl)
AT (1) ATE493132T1 (pl)
DE (2) DE102007011486A1 (pl)
ES (1) ES2356408T3 (pl)
PL (1) PL2131847T3 (pl)
WO (1) WO2008107099A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3435977A4 (en) 2016-04-01 2019-10-16 Therapeuticsmd, Inc. PHARMACEUTICAL COMPOSITION OF STEROID HORMONE
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1061036A (en) * 1962-10-27 1967-03-08 Ayerst Mckenna & Harrison Steroidal 6-chloro-4,6-dienes and preparation thereof
US4171358A (en) * 1974-04-19 1979-10-16 Eli Lilly And Company Novel contraceptive method
DE4339934C2 (de) * 1993-05-07 1995-05-24 Klaus Dr Med Umbreit Ovulationshemmendes Mittel zur hormonalen Kontrazeption
DE19739916C2 (de) * 1997-09-11 2001-09-13 Hesch Rolf Dieter Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen
US6214815B1 (en) * 1998-12-23 2001-04-10 Ortho-Mcneil Pharmaceuticals, Inc. Triphasic oral contraceptive
DE10045380A1 (de) * 2000-09-14 2002-04-04 Schering Ag Verfahren zur Kontrazeption und dessen Darreichungsform
WO2006013464A1 (en) * 2004-07-27 2006-02-09 Amistad Pharma Sas Hormone replacement therapy comprising a combination of 17-beta-oestradiol and chlormadinone acetate
TW200726473A (en) * 2005-06-28 2007-07-16 Wyeth Corp Compositions and methods for treatment of cycle-related symptoms
DE102006003509A1 (de) * 2006-01-24 2007-07-26 Grünenthal GmbH Kontrazeptivum
DE102006003508A1 (de) * 2006-01-24 2007-07-26 Grünenthal GmbH Arzneimittel umfassend eine Hormonkombination

Also Published As

Publication number Publication date
ES2356408T3 (es) 2011-04-07
US20100063014A1 (en) 2010-03-11
WO2008107099A1 (de) 2008-09-12
DE102007011486A1 (de) 2008-09-11
DE502008002148D1 (de) 2011-02-10
EP2131847A1 (de) 2009-12-16
US8361995B2 (en) 2013-01-29
ATE493132T1 (de) 2011-01-15
EP2131847B1 (de) 2010-12-29

Similar Documents

Publication Publication Date Title
PL2131847T3 (pl) Lek zawierający przynajmniej jeden gestagen
EP2585024B1 (en) Once-a-month method of contraception
BR112012014059A8 (pt) gel transdérmico de progestina / estradiol.
GEP20105066B (en) Sex steroid precursors alone or in combination with a selective estrogen receptor modulator and/or with estrogens and/or a type 5 cgmp phosphodiesterase inhibitor for the prevention and treatment of vaginal dryness and sexual dysfunction in postmenopausal women
RS20060348A (en) Extended use combination comprising estrogens and progestins
JP2019163318A5 (pl)
EA201200377A1 (ru) Способ пероральной контрацепции у женщин, способ управления нежелательными кровотечениями и предназначенная для применения в этих способах фармацевтическая упаковка
WO2005077968A3 (en) 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity
DK1443966T3 (da) Fremgangsmåde til forebyggelse eller behandling af benigne gynækologiske lidelser
AR049197A1 (es) Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona
NO327588B1 (no) Farmasoytisk sammensetning og preparat omfattende etinylostradiol og drospirenon for anvendelse som antikonsepsjonsmiddel
PL1978970T3 (pl) Środek antykoncepcyjny
PE20070119A1 (es) Nuevos regimenes para dispositivos de suministro controlado de farmacos para la anticoncepcion
BRPI0511864A (pt) uso de uma combinação de etinilestradiol e acetato de clormadinona para a preparação de um medicamento
EP1857111A3 (en) Composition comprising a combination of an aromatase inhibitor, a progestin and an estrogen, and its use for the treatment of endometriosis
ATE395047T1 (de) Feste perorale arzneiform zur kontrazeption, die dienogest und ethinylestradiol enthält
HRP20090256T1 (en) Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method
TW200640468A (en) Pharmaceutical product for oral contraception
EP1652526A3 (en) Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder
TN2010000007A1 (en) 8-beta- substituted estratrienes as selectively active estrogens
Guideline Correction: FSRH guideline (January 2019) combined hormonal contraception
CR20230127A (es) Nueva composición de anticonceptivo oral de liberación modificada
TH98166B (th) การจัดการการเกิดการตกเลือดอย่างมากในการจัดควบคุมยาคุมกำเนิดชนิดฮอร์โมนแบบมีการขยายเวลา
PL1937274T3 (pl) Zastosowanie walerianianu estradiolu w połączeniu z dienogestem do doustnej terapii dysfunkcyjnego krwawienia macicznego wraz z doustną antykoncepcją
Shulman et al. Oral contraception: from birth control to pregnancy prevention with noncontraceptive benefits